A patient tries her first antidepressant for six weeks with no real change, switches to a second, waits another six weeks, then a third. More than a year into treatment, she is still depressed, just exhausted from a cycle of trial and error that was never explained to her as a distinct clinical category with its own name. That category, treatment-resistant depression, affects a meaningful share of people diagnosed with major depression, and understanding it changes what the next step in treatment should actually look like.
What to know
Treatment-resistant depression is a specific clinical designation, not a vague description of depression that feels stubborn, generally defined as inadequate response to at least two different antidepressants taken at adequate doses.
The condition affects a substantial share of the millions of US adults living with major depressive disorder, not a rare or unusual subset.
Esketamine (Spravato) works through a different brain mechanism than standard antidepressants, which is part of why it can help some patients who did not respond to the standard oral options.
What Treatment-Resistant Depression Actually Means
Answer first: treatment-resistant depression is not a subjective label for depression that feels hard to treat. It has a specific clinical definition, and it affects a large share of people living with major depressive disorder. NPR's coverage of the FDA's expanded Spravato approval notes that major depressive disorder affects more than 20 million adults in the US, and about one in three of them do not respond to oral antidepressants alone, a gap significant enough to shape both FDA drug approvals and clinical treatment guidelines specifically around this patient population.
That one-in-three figure is the part most patients are never told plainly. Cycling through multiple medications without improvement is not a sign that nothing will work. It is often the exact pattern that defines this specific, well-studied clinical category.
Why Patients Often Cycle Through Years of Ineffective Treatment
Standard treatment protocols generally call for trying at least two full courses of oral antidepressants, each requiring roughly four to six weeks to assess properly, before a diagnosis of treatment resistance is formally considered. That sequencing exists for good clinical reasons, but it also means a patient can spend the better part of a year in trial and error before treatment-resistant depression is named as the actual problem, rather than treated as a series of individually disappointing medication attempts. Village TMS's treatment-resistant depression care is built specifically around recognizing that pattern earlier and moving to next-line options without unnecessary additional delay once the criteria are clearly met.
The cost of that delay is not abstract. Every additional month spent on a medication unlikely to work is a month of ongoing depressive symptoms, with real effects on work, relationships, and daily functioning that do not pause while the next prescription is being evaluated.
What a Proper Evaluation for TRD Actually Involves
Confirming treatment-resistant depression is not simply a matter of counting failed prescriptions. A thorough evaluation reviews the dose and duration of each prior antidepressant trial to confirm they were genuinely adequate, not cut short by side effects or inconsistent adherence, since an underdosed or interrupted trial does not count as a true failure of that medication. It also screens for commonly missed contributors, undiagnosed bipolar disorder, thyroid dysfunction, and substance use, any of which can make standard depression treatment look ineffective when the actual issue lies elsewhere.
Skipping that thorough review is how patients sometimes end up mislabeled as treatment-resistant when a different diagnosis was the real explanation all along, or conversely, how genuinely treatment-resistant patients get cycled through a fourth and fifth oral antidepressant instead of being offered a fundamentally different mechanism sooner. Getting the diagnosis right at this stage determines whether the next step in care is actually going to help or just extend the same ineffective pattern further.
Why More NYC Patients Are Turning to Spravato
Esketamine, marketed as Spravato, works on the brain's glutamate system rather than the serotonin and norepinephrine pathways that standard antidepressants target, which is part of why it can help some patients whose depression did not respond to those more conventional mechanisms. The FDA originally approved it in 2019 for use alongside an oral antidepressant, then expanded that approval in January 2025 to allow it as a standalone monotherapy, based on trial data showing it worked on its own without requiring a concurrent oral medication. Spravato treatment offered in NYC reflects that expanded approval, giving patients a path to this treatment without first needing to add another oral medication into an already frustrating rotation.
Patients considering it are often the same ones who have already tried the standard sequence in good faith, sometimes more than once, and are looking for an option that does not simply repeat the same mechanism that already failed to help them.
What This Means for Patients Who Feel Out of Options
Feeling like nothing has worked is a common experience among people with treatment-resistant depression, but it is not the same thing as having exhausted the actual options. The category exists precisely because the standard sequence of oral antidepressants does not work for everyone, and the treatments developed specifically for this population, including esketamine, exist because researchers recognized that gap and built something to address it directly.
The most useful shift for a patient stuck in this cycle is naming it accurately. Treatment-resistant depression is not a dead end. It is a specific diagnosis with its own evidence-based next steps, and reaching that diagnosis sooner, rather than quietly cycling through another round of the same medications, is often the difference that actually moves treatment forward.
A useful question to bring to a next appointment is simply whether the current treatment plan has ever been evaluated against the treatment-resistant depression criteria specifically, rather than continuing on the assumption that the next medication switch is the right move by default. That single question, asked directly, is often what finally moves a stalled treatment plan onto a path built for the actual diagnosis.
Work produced and reviewed by the Article Forge Hub editorial desk. Every piece published under this byline has been read against our sourcing, disclosure and correction standards before it went live. Corrections and enquiries are handled by the desk directly.
View all posts by Article
